Hasil Pencarian - Eike Gallmeier

  • Menampilkan 1 - 7 hasil dari 7
Perbaiki Hasil
  1. 1
    Contrast-Enhanced Ultrasound in the Follow-Up of Choroidal Melanoma Patients: Features of Liver Metastasis Arising Several Years after Treatment of the Primary Tumor

    Contrast-Enhanced Ultrasound in the Follow-Up of Choroidal Melanoma Patients: Features of Liver Metastasis Arising Several Years after Treatment of the Primary Tumor oleh Enrico N. De Toni, Eike Gallmeier, Christoph J. Auernhammer, Dirk-André Clevert

    Diterbitkan 2011-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Ultra-fast high-resolution agarose electrophoresis of DNA and RNA using low-molarity conductive media

    Ultra-fast high-resolution agarose electrophoresis of DNA and RNA using low-molarity conductive media oleh Jonathan R. Brody, Eric S. Calhoun, Eike Gallmeier, Talisa D. Creavalle, Scott E. Kern

    Diterbitkan 2004-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Synthetic lethality between ATR and POLA1 reveals a potential new target for individualized cancer therapy

    Synthetic lethality between ATR and POLA1 reveals a potential new target for individualized cancer therapy oleh Hanna Elisabeth Schneider, Lisa-Maria Schmitt, Albert Job, Brigitte Lankat-Buttgereit, Thomas Gress, Malte Buchholz, Eike Gallmeier

    Diterbitkan 2024-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Inactivation of PRIM1 Function Sensitizes Cancer Cells to ATR and CHK1 Inhibitors

    Inactivation of PRIM1 Function Sensitizes Cancer Cells to ATR and CHK1 Inhibitors oleh Albert Job, Lisa-Maria Schmitt, Lisa von Wenserski, Brigitte Lankat-Buttgereit, Thomas M. Gress, Malte Buchholz, Eike Gallmeier

    Diterbitkan 2018-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Loss of TRAIL-receptors is a recurrent feature in pancreatic cancer and determines the prognosis of patients with no nodal metastasis after surgery.

    Loss of TRAIL-receptors is a recurrent feature in pancreatic cancer and determines the prognosis of patients with no nodal metastasis after surgery. oleh Eike Gallmeier, Dominik C Bader, Lydia Kriegl, Sabina Berezowska, Hendrik Seeliger, Burkhard Göke, Thomas Kirchner, Christiane Bruns, Enrico N De Toni

    Diterbitkan 2013-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Microsatellite instability, KRAS mutations and cellular distribution of TRAIL-receptors in early stage colorectal cancer.

    Microsatellite instability, KRAS mutations and cellular distribution of TRAIL-receptors in early stage colorectal cancer. oleh Lydia Kriegl, Andreas Jung, David Horst, Antonia Rizzani, Rene Jackstadt, Heiko Hermeking, Eike Gallmeier, Alexander L Gerbes, Thomas Kirchner, Burkhard Göke, Enrico N De Toni

    Diterbitkan 2012-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group

    Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled... oleh Thomas J. Ettrich, Andreas W. Berger, Lukas Perkhofer, Severin Daum, Alexander König, Andreas Dickhut, Uwe Wittel, Kai Wille, Michael Geissler, Hana Algül, Eike Gallmeier, Jens Atzpodien, Marko Kornmann, Rainer Muche, Nicole Prasnikar, Andrea Tannapfel, Anke Reinacher-Schick, Waldemar Uhl, Thomas Seufferlein

    Diterbitkan 2018-12-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: